Apellis: EU's CHMP Adopts Negative Opinion For Pegcetacoplan For GA; To Seek Re-Examination Of MAA
Apellis Pharmaceuticals, Inc. (APLS) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a negative opinion for Pegcetacoplan for geographic atrophy or GA.
Jeffrey Eisele More Such Health News Apellis Pharmaceuticals Inc Apellis Pharmaceuticals European Medicines Agency Medicinal Products
Source: rttnews.com